Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy. Issue 4 (16th December 2020)

• Record Type: Journal Article
• Authors: Carey, Ryan M.; Shimunov, David; Weinstein, Gregory S.; Cannady, Steven B.; Lukens, John N.; Lin, Alexander; Swisher‐McClure, Samuel; Bauml, Joshua M.; Aggarwal, Charu; Cohen, Roger B.; Newman, Jason G.; Chalian, Ara A.; Rassekh, Christopher H.; Basu, Devraj; O'Malley, Bert W.; Rajasekaran, Karthik; Brody, Robert M.
• Is Part Of: Head & neck. Volume 43:Issue 4(2021)
• Page Start: 1128
• Page End: 1141
• Publication Date: 2020-12-16
• Subjects: adjuvant therapy -- head and neck cancer -- oropharyngeal cancer -- overall survival -- radiation therapy -- recurrence -- TORS; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26578
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Some patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) do not receive guideline‐recommended postoperative radiation therapy (PORT) following primary transoral robotic surgery (TORS). Methods: Three‐hundred and sixty‐four patients with treatment‐naïve, HPV‐associated OPSCC were recommended to receive PORT based on clinicopathological features following TORS. Patients were stratified based on if they received PORT. Oncologic outcomes were compared. Results: The 3‐year locoregional failure (LRF) was 32% in patients who did not receive PORT and 4% in patients who received PORT ( P < .001). Despite increased LRF, avoiding PORT was not associated with increased 3‐year distant metastasis rates (8% vs 4%, P = .56) or worse 3‐year survival (95% vs 98%, P = .34). Recurrences in the surgery alone cohort varied between local and regional sites and were often successfully salvaged. Conclusions: Patients with HPV‐associated OPSCC who do not receive indicated PORT have an increased risk of LRF but similar survival due to high salvage rates.